Shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price target of $3.00 for the company and are anticipating that the company will post ($0.02) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Rexahn Pharmaceuticals an industry rank of 92 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research cut shares of Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/analysts-set-3-00-price-target-for-rexahn-pharmaceuticals-inc-nysernn.html

Rexahn Pharmaceuticals (NYSE:RNN) traded up 2.3743% during trading on Tuesday, reaching $0.2199. The company’s stock had a trading volume of 259,389 shares. The stock’s market capitalization is $46.91 million. The firm has a 50 day moving average of $0.26 and a 200 day moving average of $0.29. Rexahn Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $0.65.

Rexahn Pharmaceuticals (NYSE:RNN) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. Analysts expect that Rexahn Pharmaceuticals will post ($0.07) EPS for the current year.

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. boosted its position in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned approximately 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent quarter.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

5 Day Chart for NYSE:RNN

Get a free copy of the Zacks research report on Rexahn Pharmaceuticals (RNN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.